NasdaqCM:EQ 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
31 Mar 24	38	-12	14	38
31 Dec 23	36	-13	14	37
30 Sep 23	43	-8	16	36
30 Jun 23	34	-18	16	36
31 Mar 23	25	-29	17	36
31 Dec 22	16	-62	17	38
30 Sep 22	0	-76	15	37
30 Jun 22	0	-72	13	35
31 Mar 22	0	-67	12	31
31 Dec 21	0	-39	11	26
30 Sep 21	0	-37	11	25
30 Jun 21	0	-34	10	23
31 Mar 21	0	-31	10	21
31 Dec 20	0	-30	10	19
30 Sep 20	0	-28	10	18
30 Jun 20	0	-28	10	18
31 Mar 20	0	-27	9	19
31 Dec 19	0	-26	9	18
30 Sep 19	0	-23	9	15
30 Jun 19	0	-22	7	12
31 Mar 19	0	-18	6	8
31 Dec 18	0	-13	4	5
30 Sep 18	0	-10	2	3

양질의 수익: EQ 은(는) 현재 수익성이 없습니다.

이익 마진 증가: EQ 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: EQ 은(는) 수익성이 없으며 지난 5년 동안 연간 4.3% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 EQ 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: EQ 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( -14.4% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: EQ 현재 수익성이 없기 때문에 마이너스 자본 수익률( -57.5% )을 갖습니다.

Equillium 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

First quarter 2024 earnings released: US$0.078 loss per share (vs US$0.11 loss in 1Q 2023)

Recent updates

Benign Growth For Equillium, Inc. (NASDAQ:EQ) Underpins Stock's 54% Plummet

Equillium, Inc. Announces Topline Data from Its Phase 2, Single Dose, Proof-Of-Concept Study of Eq101

Equillium, Inc. Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

New minor risk - Profitability

Forecast to breakeven in 2024

First quarter 2024 earnings released: US$0.078 loss per share (vs US$0.11 loss in 1Q 2023)

We Think Equillium (NASDAQ:EQ) Needs To Drive Business Growth Carefully

Price target increased by 9.5% to US$6.75

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1B Equalise Study of Itolizumab in Lupus Nephritis

Consensus EPS estimates fall by 188%

Little Excitement Around Equillium, Inc.'s (NASDAQ:EQ) Revenues

New major risk - Share price stability

Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease

New minor risk - Share price stability

Price target decreased by 10% to US$6.17

Equillium, Inc. Presents Positive Data from Phase 1B EQUALISE Study At the 2023 Annual Meeting of the American College of Rheumatology

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

Equillium Gets an Additional 180-Day Grace Period to Regain Compliance with the Minimum Bid Price Requirement

Consensus revenue estimates increase by 23%

Analyst Forecasts For Equillium, Inc. (NASDAQ:EQ) Are Surging Higher

Earnings Release: Here's Why Analysts Cut Their Equillium, Inc. (NASDAQ:EQ) Price Target To US$6.06

Equillium, Inc. Promotes Maple Fung to the Position of Chief Medical Officer

Equillium, Inc. (NasdaqGM:EQ) announces an Equity Buyback for $7.5 million worth of its shares.

Consensus revenue estimates increase by 187%

Broker Revenue Forecasts For Equillium, Inc. (NASDAQ:EQ) Are Surging Higher

Consensus revenue estimates increase by 17%

Does Equillium (NASDAQ:EQ) Have A Healthy Balance Sheet?

Biocon Limited in Collaboration with Equillium, Inc. Initiate Phase 2 Clinical Study of Itolizumab in Patients with Ulcerative Colitis

Price target decreased to US$12.00

Insufficient new directors

Equillium, Inc. Announces Initiation of Phase 2 Study of Eq101 A First-In-Class Multi-Cytokine Inhibitor of Il-2, Il-9 and Il-15 Targeting Alopecia Areata

Equillium Announces Initiation of Phase 1 study of EQ102, A First-in-Class Multi-Cytokine Inhibitor of IL-15 and IL-21 Targeting Celiac Disease

Price target decreased to US$12.00

Price target increased to US$14.00

Equillium, Inc. Reports Interim Results from the Type B Portion of the EQUALIZE Study Evaluating Itolizumab

Equillium, Inc. (NasdaqGM:EQ) entered into a definitive merger agreement to acquire Metacrine, Inc. (NasdaqCM:MTCR).

Equillium GAAP EPS of -$0.41 in-line

Insufficient new directors

Price target increased to US$13.75

Equillium, Inc., Annual General Meeting, May 24, 2022

Equillium, Inc. Announces Initiation of the Phase 3 EQUATOR Study of Itolizumab in First-line Acute Graft-Versus-Host Disease

Equillium, Inc. Appoints Barbara Troupin to its Board of Directors and as Member of Nominating and Corporate Governance Committee

Price target decreased to US$12.50

Equillium, Inc. (NasdaqGM:EQ) completed the acquisition of Bioniz Therapeutics, Inc. from Kevin Green for $330 million.

Equillium Announces Data from Phase 1B Equip Study in Patients with Uncontrolled Asthma

Senior VP & COO notifies of intention to sell stock

Equillium CEO Bruce Steel - Drugs For Autoimmune, Inflammatory Disorders (Video)

Equillium Announces Update to EQUALISE Study of Itolizumab in Patients with Systemic Lupus Erythematosus and Lupus Nephritis

Equillium, Inc. Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDA

Equillium, Inc.(NasdaqGM:EQ) dropped from Russell Microcap Value Index

Equillium Inc Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease

Equillium Presents Data on Target Engagement and Modulation of Cd6 on T Cells with Itolizumab at the International Society for Advancement of Cytometry

Chief Scientific Officer & Director exercised options and sold US$138k worth of stock

Price target decreased to US$13.75

Equillium Announces Oral Presentation Highlighting Positive Data from the EQUATE Study in Acute Graft-Versus-Host Disease at the EHA2021 Virtual Congress of the European Hematology Association

Consultant notifies of intention to sell stock

Equillium, Inc. Announces Positive Data Supporting the Role of Itolizumab as A Potential Treatment for Acute Graft-Versus-Host Disease

Is Equillium, Inc.'s (NASDAQ:EQ) Shareholder Ownership Skewed Towards Insiders?

Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience

New 90-day high: US$9.61

Equillium, Inc. Appoints Yu (Katherine) Xu, Ph.D., as A Class II Director

Equillium prices $30M registered direct offering

Equillium, Inc.(NasdaqGM:EQ) dropped from Russell 2000 Dynamic Index

New 90-day high: US$6.80

Equillium, Inc. Appoints Dolca Thomas as Executive Vice President of Research & Development and Chief Medical Officer, Effective January 11, 2021

Equillium (EQ) Investor Presentation - Slideshow

Price target lowered to US$16.25

How Much Of Equillium, Inc. (NASDAQ:EQ) Do Insiders Own?

Equillium Announces Positive Interim Data of Itolizumab in the First-Line Treatment of Acute Graft-Versus-Host Disease

Equillium, Inc. to Present Data at the 2020 American College of Rheumatology Meeting Demonstrating CD6 Modulation Improves Kidney and Skin Pathology in Preclinical Models of Systemic Lupus Erythematosus

New 90-day low: US$5.04

FDA gives green signal to Equillium's late-stage COVID-19 trial

Equillium, Inc. Announces Plan to Develop EQ001 for the Treatment of Lupus Nephritis

Equillium, Inc. Announces Executive Changes